



DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration  
Silver Spring, MD 20993

NDA 209354

**NDA APPROVAL**

Bausch Health Americas, Inc.  
Attention: Sean Humphrey  
Associate Director, Global Regulatory Affairs  
1330 Redwood Way, Suite C  
Petaluma, CA 94954

Dear Mr. Humphrey:

Please refer to your New Drug Application (NDA) dated and received on August 18, 2017 submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for DUOBRII™ (halobetasol propionate and tazarotene) Lotion, 0.01%/0.045%.

We acknowledge receipt of your amendment dated August 14, 2018, which constituted a complete response to our June 15, 2018, action letter.

This new drug application provides for the use of DUOBRII™ (halobetasol propionate and tazarotene) Lotion, 0.01%/0.045% for the topical treatment of plaque psoriasis in adults.

**APPROVAL & LABELING**

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information, and Patient Package Insert) as well as annual reportable changes not included in the enclosed labeling. Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*, available at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>

The SPL will be accessible via publicly available labeling repositories.

## **CARTON AND CONTAINER LABELING**

Submit final printed carton and container labeling that are identical to the enclosed carton and container labeling submitted on April 19, 2019 as soon as they are available, but no more than 30 days after they are printed. Please submit these labeling electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (April 2018, Revision 5)*. For administrative purposes, designate this submission “**Final Printed Carton and Container Labeling for approved NDA 209354.**” Approval of this submission by FDA is not required before the labeling is used.

## **REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are waiving the pediatric study requirement for ages 0 to less than 4 years of age because the necessary studies are impossible or highly impracticable. This is because the prevalence of moderate to severe psoriasis in pediatric population in this age group is low.

We are deferring submission of your pediatric study for ages 4 to less than 17 years of age for this application because pediatric studies should be delayed until additional safety or effectiveness data have been collected in adults. Halobetasol propionate is a potent to super potent corticosteroid and tazarotene has a potential to enhance absorption of the co-administered drugs. Therefore safety data in adults is needed prior to proceeding in to younger age cohorts.

Your deferred pediatric study required by section 505B(a) of the FDCA are required postmarketing study. The status of this postmarketing study must be reported annually according to 21 CFR 314.81 and section 505B(a)(4)(C) of the FDCA. This required study is listed below.

3611-1	Pharmacokinetic (PK)/hypothalamic-pituitary-adrenal (HPA) axis suppression/safety open-label study of halobetasol propionate and tazarotene lotion, 0.01%/0.045% in 45 pediatric subjects age 4 to less than 17 years with moderate to severe plaque psoriasis. PK and HPA axis suppression assessments should be done in at least 20 evaluable subjects under maximal use conditions.
--------	--

Final Protocol Submission:	06/2019
Study/Trial Completion:	06/2022
Final Report Submission:	12/2022

Submit the protocol to your IND with a cross-reference letter to this NDA.

Reports of this/these required pediatric postmarketing study(ies) must be submitted as a new drug application (NDA) or as a supplement to your approved NDA with the proposed labeling changes you believe are warranted based on the data derived from these studies. When submitting the reports, please clearly mark your submission "**SUBMISSION OF REQUIRED PEDIATRIC ASSESSMENTS**" in large font, bolded type at the beginning of the cover letter of the submission.

### **PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the Prescribing Information, Medication Guide, and Patient Package Insert (as applicable) to:

OPDP Regulatory Project Manager  
Food and Drug Administration  
Center for Drug Evaluation and Research  
Office of Prescription Drug Promotion  
5901-B Ammendale Road  
Beltsville, MD 20705-1266

Alternatively, you may submit a request for advisory comments electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft Guidance for Industry (available at:

<http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM443702.pdf> ).

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the Prescribing Information, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. Form FDA 2253 is available at

<http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>.

Information and Instructions for completing the form can be found at

<http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>.

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Strother Dixon, Senior Regulatory Project Manager, at 301 796-1015.

Sincerely,

*{See appended electronic signature page}*

Jill A Lindstrom, MD, FAAD  
Deputy Director  
Division of Dermatology and Dental Products  
Office of Drug Evaluation III  
Center for Drug Evaluation and Research

ENCLOSURE(S):

Content of Labeling  
Prescribing Information  
Patient Package Insert or Medication Guide  
Carton and Container Labeling

-----  
**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**  
-----

/s/  
-----

JILL A LINDSTROM  
04/25/2019 12:16:48 PM